Skip to main content
NCBI home page
Cell Proliferation logoLink to Cell Proliferation
. 2003 Jan 31;32(4):231–238. doi: 10.1046/j.1365-2184.1999.3240231.x

Phenotypic and genotypic alterations characterize patients bearing plasma cell dyscrasias with a high M‐component

C Greco 1, F Ameglio 2, F Alvino 1, A Mosiello 1, A M Cianciulli 1, I Venturo 3, G Del Monte 3, M Giampaolo 4, A W Tong 5, G M Gandolfo 1
PMCID: PMC6726327  PMID: 10614712

Abstract

Abstract. As at present only a long‐term follow‐up can fully determine whether monoclonal gammapathies of undetermined significance (MGUS) will evolve into multiple myeloma (MM), this study attempted to identify other variables connected with the amount of monoclonal component (MC), generally considered as the most reliable marker of malignant evolution. Thirty‐four MGUS subjects showing a high MC (≥ 15.0 g/l) but without clinical evidence of MM (MGUS group b), were characterized for their phenotypic and genotypic profile by comparing them either with 40 MM patients or with 24 subjects affected by a benign form of monoclonal gammapathy (MGUS group a) according to the standard criteria. In addition to the usual laboratory markers, the levels of expression of a panel of CD membrane subsets were measured on B and T lymphocytes. Also, the serum level of the p53 mutant protein and the structural alterations of the c‐myc oncogene were evaluated. The results show that for MGUS group b patients, an increased M‐protein was accompanied by significantly increased levels of peripheral blood CD3+ T cells and oncogenetic aberrations in c‐myc. Since a high serum MC level seems to indicate a greater likelihood of malignant transformation for MGUS patients, these findings suggest that this relationship may be a result of the concomitant alterations observed at a phenotypic and genotypic level. Such alterations may be potentially useful as surrogate markers for the transition of benign to malignant (MM) plasma cell dyscrasia.

Full Text

The Full Text of this article is available as a PDF (1.0 MB).

REFERENCES

  1. Aguzzi F, Bergami MR, Gasparro C, Bellotti V, Merlini G. (1992) Occurrence of monoclonal components in general practice: clinical implications. Eur J. Haematol. 48, 192. [DOI] [PubMed] [Google Scholar]
  2. Baldini L, Guffanti A, Cesana BM et al. (1996) Role of different hematologic variables in defining the risk of malignant transformation in monoclonal gammopathy. Blood 87, 912. [PubMed] [Google Scholar]
  3. Bataille R, Jourdan M, Zhang XG, Klein B. (1989) Serum levels of interleukin‐6, a potent myeloma cell growth factor, as a reflection of disease severity in plasma cell dyscrasias. J. Clin. Invest 84, 2008. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Blade J, Lopez‐guillermo A, Rozman C et al. (1992) Malignant transformation and life expectancy in monoclonal gammopathy of undetermined significance. Br. J. Haematol. 81, 391. [DOI] [PubMed] [Google Scholar]
  5. Cianciulli AM, Coletta AM, Pescatore B et al. (1997) Monoclonal gammapathy and multiple myeloma: incidence of chromosomal aneuploidy detected by interphase fluorescence in situ hybridization. Eur J. Histochem. 14, 157. [PubMed] [Google Scholar]
  6. Croce C. (1987) Role of chromosome translocations in human neoplasia. Cell 49, 155. [DOI] [PubMed] [Google Scholar]
  7. Durie BGM, Salmon SE. (1975) A clinical staging system for multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival. Cancer 36, 842. [DOI] [PubMed] [Google Scholar]
  8. Foon KA, Todd RF. (1986) Immunologic classification of leukemias and lymphomas. Blood 68, 1. [PubMed] [Google Scholar]
  9. Ganjoo RK, Malpas JS. (1995. Plasmacytoma In: Malpas JS, Bergsagel DE, Kyle RA, eds. Myeloma: Biology and Management. Oxford : University Press, 463. [Google Scholar]
  10. Greco C, Gandolfo GM, Mattei F et al. (1994) Detection of c‐myb genetic alterations and mutant p53 serum protein in patients with benign and malignant colon lesions. Anticancer Res. 14, 1433. [PubMed] [Google Scholar]
  11. Greil R, Fasching B, Loidl P, Huber H. (1991) Expression of the c‐myc proto‐oncogene in multiple myeloma and chronic lymphocytic leukemia: an in situ analysis. Blood 78, 180. [PubMed] [Google Scholar]
  12. Humphries JE, Williams ME. (1993) Detectability of immunoglobulin and c‐myc gene rearrangements in multiple myeloma. Br. J. Haematol. 83, 173. [DOI] [PubMed] [Google Scholar]
  13. Imamura J, Miyoshi I, Koeffler HP. (1994) P53 in hematologic malignancies. Blood 84, 2412. [PubMed] [Google Scholar]
  14. Kay NE, Leong T, Kyle RA et al. (1997) Circulating blood B cells in multiple myeloma: analysis and relationship to circulating clonal cells and clinical parameters in a cohort of patients entered on the Eastern Cooperative Oncology Group phase III E9486 Clinical Trial. Blood 90, 340. [PubMed] [Google Scholar]
  15. Kay NE, Oken MM, Bone N et al. (1995) Circulating CD19+ blood cell levels in meloma. Blood 86, 4000. [PubMed] [Google Scholar]
  16. Knowles DM, Chadburn A, Inghirami G. (1992. Immunophenotypic markers useful in the diagnosis and classification of hematopoietic neoplasms In: Knowles DM, ed. Neoplastic Hematopathology. Baltimore : Williams & Wilkins, 73. [Google Scholar]
  17. Kyle RA. (1984) “Benign” monoclonal gammapathy. JAMA 251, 1849. [PubMed] [Google Scholar]
  18. Kyle RA. (1992) Diagnostic criteria of multiple myeloma. Hematol. Oncol. Clin. North America 6, 347. [PubMed] [Google Scholar]
  19. Miller R, Phillips R. (1969) Separation of cells by velocity sedimentation. J. Cell Physiol. 73, 191. [DOI] [PubMed] [Google Scholar]
  20. Møller‐petersen J, Schmidt EB. (1986. Diagnostic value of the concentration of M‐component in initial classification of monoclonal gammopathy. Scand. J. Haematol. 36, 295. [DOI] [PubMed] [Google Scholar]
  21. Neri A, Baldini L, Trecca D, Cro L, Polli E, Maiolo AT. (1993) P53 gene mutations in multiple myeloma are associated with advanced forms of malignancy. Blood 81, 128. [PubMed] [Google Scholar]
  22. Peltomäki P, Alfthan O, De La Chapelle A. (1991) Oncogenes in human testicular cancer. DNA and RNA Studies. Br. J. Cancer 63, 851. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Pilarski LM, Masellis‐smith A, Szczepek A, Mant MJ, Belch AR. (1996) Circulating clonotypic B cells in the biology of multiple myeloma: speculations on the origin of myeloma. Leuk. Lymphoma 22, 375. [DOI] [PubMed] [Google Scholar]
  24. San Miguel JF, Caballero MD, Gonzales M. (1985) T‐cell subpopulations in patients with monoclonal gammapathies. Am. J. Hematol. 20, 267. [DOI] [PubMed] [Google Scholar]
  25. Van Riet I, Heirman C, Lacor P, De Waele M, Thielemans K, Van Camp B. (1989) Detection of monoclonal B lymphocytes in bone marrow and peripheral blood of multiple myeloma patients by immunoglobulin gene rearrangement studies. Br. J. Haematol. 73, 289. [DOI] [PubMed] [Google Scholar]

Articles from Cell Proliferation are provided here courtesy of Wiley

RESOURCES